Clopidogrel is classified as FDA pregnancy risk category B. Last reviewed on RxList: If a breast-feeding infant experiences an adverse effect related to a maternally administered drug, healthcare providers are encouraged to report the adverse effect to the FDA.
Major Treatment with drotrecogin alfa should be carefully considered in patients who are receiving or have received any platelet inhibitors within 7 days.
Use caution in patients receiving either anticoagulants, including heparin and warfarin, or other platelet aggregation inhibitors; risk of bleeding increases. Recent MI, Recent Stroke, or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction MIrecent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke fatal or notnew MI fatal or notand other vascular death.
Moderate Due to the risk for terbinafine related adverse effects, caution is advised when coadministering clopidogrel.
Patients should be instructed to monitor for signs and symptoms of bleeding while taking an SNRI with a platelet inhibitor and to promptly report any bleeding events to the practitioner. Patients should be instructed to monitor for signs and symptoms of bleeding while taking trazodone concurrently with an antiplatelet medication and to promptly report any bleeding events to the practitioner.
Concomitant use of certain inhibitors of this enzyme results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition. The mean duration of treatment was 23 months. Contact the applicable plan provider for the most current information. Muscle pain, back pain, muscle weakness.
Consider alternative therapy to fluoxetine, if possible. CYP2C19 poor metabolizers associated with diminished antiplatelet response to clopidogrel; although higher-dose regimen mg loading dose followed by mg once daily in poor metabolizers increases antiplatelet response, no appropriate dosing regimen for poor metabolizers has been established in clinical outcome trials.
Severe According to the manufacturer, concomitant use of dasabuvir; ombitasvir; paritaprevir; ritonavir with stong CYP2C8 inhibitors is contraindicated due to the potential for dasabuvir-induced QT prolongation. Ask your pharmacist about using these products safely.
Thus, clopidogrel could increase plasma concentrations of drugs metabolized by this isoenzyme, such as torsemide. Specific guidelines for dosage adjustments in hepatic impairment are not available; it appears that no dosage adjustments are needed.
Although there are no in vivo data with which to predict the magnitude or clinical significance of this potential interaction, caution should be used when nateglinide is coadministered with clopidogrel.
Austria-Codex in German 62nd ed. Medicines are sometimes used for purposes other than those listed in a Medication Guide. Although this interaction has not been studied by the manufacturer, and published literature suggests the potential for interactions to be low, taking these drugs together may increase the systemic exposure of terbinafine.
Use clopidogrel and nicardipine together with caution and monitor for reduced efficacy of clopidogrel. Buerger's disease or thromboangiitis obliterans is a condition that reduces blood supply to the hands and feet in smokers.